Uncategorized Archives - Page 37 of 142

MondayJan 23, 2023 9:45 am

MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

MetAlert’s CEO, Patrick Bertagna, while appearing in an interview presented by Sequire Spotlight and hosted by Carmel Fisher, expressed his optimism for the new year while also sharing the company’s recent progress He discussed the company’s core objective- increasing the quality of life, and longevity of people living with Alzheimer’s, dementia, and autism (“ADA”) Bertagna also hinted at potential acquisitions by the company, attributing it to extensive efforts over the past couple of years to clean up its balance sheet He noted that as MetAlert’s revenue per user continues to grow, its margins will increase, ultimately placing the company in…

ThursdayJan 19, 2023 9:00 am

MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

MetAlert recently signed a Letter of Intent to acquire Florida-based TrakTec in a cash and stock deal worth $4.5 million TrakTec manufactures and sells affordable location awareness technology solutions for consumer, enterprise, and government applications The planned acquisitions will bring on board synergistic and complementary technologies that fit in with MetAlert’s subscription model and existing suite of location-sensitive and tracking solutions The acquisition is also set to offer both short- and long-term benefits, eventually contributing to the company’s efforts to up-list MetAlert (OTC: MLRT), a pioneer in location-sensitive wearable technology products and human and health monitoring devices, is looking to…

TuesdayJan 17, 2023 12:00 pm

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

Believed to be the first natural low-doses of THC-based compound to enter human trials for Alzheimer’s IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease The clinical trial is expected to produce data to “help us to further understand the metabolism of IGC-AD1 for a diverse population,” says CEO In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease (https://nnw.fm/Y1rLN). Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to…

TuesdayJan 17, 2023 10:30 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

BiondVax is developing a pipeline of nanosized antibody (“NanoAb”) therapies addressing diseases with large underserved medical needs and attractive commercial opportunities BiondVax recently announced results from a preclinical in vivo proof-of-concept study indicating its innovative inhaled NanoAb COVID-19 therapy virtually eliminates viral presence in the lungs and leads to significantly shorter and milder illness BiondVax CEO Amir Reichman presented at the Biotech Showcase Conference, where he discussed recent successful results from the preclinical in vivo study, additional pipeline plans for other NanoAb therapeutics, and the company’s derisked R&D strategy Mainland China is experiencing a fresh wave of COVID-19 infections sweeping…

FridayJan 13, 2023 9:45 am

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an opportunity for remote monitoring of patients’ whereabouts To meet the need, MetAlert developed a pioneering wearable GPS-enabled tracking device a decade ago that unobtrusively slips into wearers’ shoes The company has since expanded the device’s…

ThursdayJan 12, 2023 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization…

TuesdayJan 10, 2023 12:00 pm

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immunotherapy(TM) (“ADI(TM)”) technology toward clinical trials Aditxt also plans to submit a Clinical Trial Application (“CTA”) for immunotherapeutic technology drug candidate ADI(TM)-100, seeking approval for Adimune(TM) to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023 ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune…

TuesdayJan 10, 2023 10:30 am

MetAlert, Inc. (MLRT) Developing Innovative Location-Sensitive Health Monitoring and Supervision Products as It Targets Market Leadership in Telehealth Space

MetAlert is a pioneer in location-sensitive health monitoring devices and wearable technology products targeting the Alzheimer’s, Dementia, and Autism (“ADA”) market The company is looking to provide cutting-edge telehealth technologies and is continuously working to roll out improved and more innovative products for its users Its SmartSole(R) product facilitates discreet tracking and remote monitoring of ADA patients The company has also launched SmartSole plus(R), which adds Bluetooth and Wi-Fi capabilities for better tracking MetAlert also distributes RoomMate, a wall-mounted 3D infrared supervision product that enables caregivers to look after patients without intruding on their personal space The policy changes spearheaded…

FridayJan 06, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform

BiondVax Pharmaceuticals was recently featured in a research report by Zacks Small-Cap Research The report highlighted BiondVax’s recent achievements, the most notable of which is the proof-of-concept animal trial that delivered positive results suggesting that the company’s anti-COVID-19 NanoAb candidate resulted in milder and shorter illness The company also received support and advice from the Paul Ehrlich Institute (“PEI”), which are viewed as key toward approval for a Phase 1/2a first-in-human clinical trial The report estimates that BiondVax is fully funded for the next 12 months; subsequent to the report’s publication, BiondVax raised an additional $7.3 million net in an…

FridayJan 06, 2023 9:45 am

MetAlert, Inc. (MLRT) – Offering More Than Location-Sensitive Health Monitoring Devices

The CDC estimates that by 2060, over 14 million Americans may be diagnosed with Alzheimer’s, up from the current 6.5 million In a surprising study, presented at the 2022 Alzheimer’s Association International Conference, it was noted that this rise could be largely attributed to people’s intake of ultra-processed foods, which was linked to a higher risk of dementia Of the 10,000 participants who took part in the study, it was noted that those who ate the most ultra-processed foods had a 28% faster rate of global cognitive decline, and a 25% faster rate of executive function decline compared to those…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

MetAlert, Inc. (MLRT) Developing Innovative Location-Sensitive Health Monitoring and Supervision Products as It Targets Market Leadership in Telehealth Space

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform

MetAlert, Inc. (MLRT) – Offering More Than Location-Sensitive Health Monitoring Devices

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search